secwatch.observer — SEC 8-K summary
======================================

Issuer:     Genprex, Inc. (GNPX)
CIK:        0001595248
Form:       8-K
Filed at:   2025-04-28T23:59:59+00:00
Accession:  0001437749-25-013235
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Genprex licenses NYU patent for Reqorsa gene therapy in mesothelioma; TUSC2 down in 84%
--------------------------------------------------------------------------------

- Exclusive patent license with NYU Langone Health for Reqorsa (quaratusugene ozeplasmid) to treat mesothelioma.
- TUSC2 tumor suppressor gene is downregulated in 84% of mesotheliomas; Reqorsa delivers TUSC2.
- Preclinical data showed decreased cell proliferation/invasion and increased apoptosis in all four MPM cell lines.
- Genprex formed a Mesothelioma Clinical Advisory Board of four leading researchers to guide the program.
- About 3,000 new US cases/yr; life expectancy 18 months, 3-year survival rate 23% with treatment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595248/000143774925013235/0001437749-25-013235-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595248/000143774925013235/gnpx20250424_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-013235

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer